S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
What's in Democrats' big bill? Climate, health care, savings
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:PODD

Insulet - PODD Stock Forecast, Price & News

$267.05
+11.04 (+4.31%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$247.55
$276.38
50-Day Range
$198.33
$267.05
52-Week Range
$181.00
$324.81
Volume
833,891 shs
Average Volume
422,491 shs
Market Capitalization
$18.52 billion
P/E Ratio
534.10
Dividend Yield
N/A
Price Target
$285.82

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
7.0% Upside
$285.82 Price Target
Short Interest
Healthy
4.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.15mentions of Insulet in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$4.64 M Sold Last Quarter
Proj. Earnings Growth
36.15%
From $1.30 to $1.77 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

505th out of 1,283 stocks

Surgical & Medical Instruments Industry

52nd out of 130 stocks

PODD stock logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Canaccord Genuity Group boosted their target price on Insulet from $250.00 to $290.00 and gave the stock a "buy" rating in a research report on Friday. Morgan Stanley reduced their target price on Insulet from $268.00 to $244.00 and set an "equal weight" rating for the company in a research report on Tuesday, June 7th. BTIG Research reduced their target price on Insulet from $310.00 to $250.00 and set a "buy" rating for the company in a research report on Friday, June 24th. Raymond James boosted their target price on Insulet from $262.00 to $280.00 in a research report on Friday. Finally, Citigroup cut Insulet from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $310.00 to $250.00 in a research report on Monday, July 11th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $289.50.

Insulet Trading Up 4.3 %

Shares of NASDAQ:PODD traded up $11.04 during midday trading on Friday, reaching $267.05. The company had a trading volume of 833,891 shares, compared to its average volume of 422,491. Insulet has a one year low of $181.00 and a one year high of $324.81. The company has a quick ratio of 4.51, a current ratio of 5.98 and a debt-to-equity ratio of 3.11. The firm's fifty day moving average price is $227.06 and its 200-day moving average price is $235.78. The stock has a market cap of $18.52 billion, a PE ratio of 534.10 and a beta of 0.73.

Insulet (NASDAQ:PODD - Get Rating) last released its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.72). The company had revenue of $299.40 million during the quarter, compared to the consensus estimate of $290.87 million. Insulet had a net margin of 2.94% and a return on equity of 13.29%. The company's revenue was up 13.8% on a year-over-year basis. During the same period last year, the firm posted $0.10 EPS. On average, equities research analysts anticipate that Insulet will post 1.3 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 15,000 shares of the company's stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the completion of the transaction, the director now owns 13,695 shares of the company's stock, valued at approximately $3,052,615.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Insulet news, Director Shacey Petrovic sold 15,000 shares of the company's stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the completion of the transaction, the director now owns 13,695 shares of the company's stock, valued at approximately $3,052,615.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Charles Alpuche sold 6,000 shares of the company's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $215.32, for a total value of $1,291,920.00. Following the transaction, the chief operating officer now directly owns 43,899 shares of the company's stock, valued at approximately $9,452,332.68. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders.

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates
Insulet (PODD) to Release Quarterly Earnings on Thursday
Insulet (NASDAQ:PODD) Rating Lowered to Neutral at Citigroup
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Company Calendar

Last Earnings
8/04/2022
Today
8/07/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,300
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$285.82
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$235.00
Forecasted Upside/Downside
+7.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$16.80 million
Pretax Margin
4.33%

Debt

Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.08 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
68,716,000
Market Cap
$18.52 billion
Optionable
Optionable
Beta
0.73

Social Links















PODD Stock - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Insulet stock.
View analyst ratings for Insulet
or view top-rated stocks.

What is Insulet's stock price forecast for 2022?

11 analysts have issued 1-year price targets for Insulet's stock. Their PODD stock forecasts range from $235.00 to $350.00. On average, they predict Insulet's stock price to reach $285.82 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

How has Insulet's stock performed in 2022?

Insulet's stock was trading at $266.07 at the beginning of the year. Since then, PODD stock has increased by 0.4% and is now trading at $267.05.
View the best growth stocks for 2022 here
.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, August, 4th. The medical instruments supplier reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by $0.72. The medical instruments supplier had revenue of $299.40 million for the quarter, compared to analysts' expectations of $290.87 million. Insulet had a net margin of 2.94% and a trailing twelve-month return on equity of 13.29%. The business's revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $322.45 million-$330.72 million, compared to the consensus revenue estimate of $309.85 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.82%), Frontier Capital Management Co. LLC (0.46%), abrdn plc (0.38%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Beacon Investment Advisory Services Inc. (0.29%) and AEGON ASSET MANAGEMENT UK Plc (0.28%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends for Insulet
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $267.05.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $18.52 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.50 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 2,300 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for Insulet is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.